tbuckley/cabot-search huggingface dataset:
Evidence-informed policy for tackling adverse climate change effects on health: Linking regional and global assessments of science to catalyse action
Authors: Robin Fears, Khairul Annuar B. Abdullah, Claudia Canales-Holzeis, Deoraj Caussy, Andy Haines, Sherilee L. Harper, Jeremy N. McNeil, Johanna Mogwitz, Volker ter Meulen
Journal: PLoS Medicine (2021)

Robin Fears and co-authors discuss evidence-informed regional and global policy responses to health impacts of climate change.
Contribution of monocyte chemoattractant protein-1 and macrophage-colony stimulating factor to coronary artery disease
Authors: Y Iso, Hiroshi Suzuki, Takatoshi Satou, Makoto Shoji, Masayuki Shibata, Yuji Hamazaki, Shinji Koba, Tetsuo Sakai, Toshihiko Otsuka, Tsukasa Saitoh, Mikitaka Murakami, Eiichi Geshi, Takashi Katagiri
Journal: Circulation (2002)
Transdisciplinary research and clinical priorities for better health
Authors: Luigi Fontana, Alessio Fasano, Yap Seng Chong, Paolo Vineis, Walter C. Willett
Journal: PLoS Medicine (2021)

Modern medicine makes it possible for many people to live with multiple chronic diseases for decades, but this has enormous social, financial, and environmental consequences. Preclinical, epidemiological, and clinical trial data have shown that many of the most common chronic diseases are largely preventable with nutritional and lifestyle interventions that are targeting well-characterized signaling pathways and the symbiotic relationship with our microbiome. Most of the research priorities and spending for health are focused on finding new molecular targets for the development of biotech and pharmaceutical products. Very little is invested in mechanism-based preventive science, medicine, and education. We believe that overly enthusiastic expectations regarding the benefits of pharmacological research for disease treatment have the potential to impact and distort not only medical research and practice but also environmental health and sustainable economic growth. Transitioning from a primarily disease-centered medical system to a balanced preventive and personalized treatment healthcare system is key to reduce social disparities in health and achieve financially sustainable, universal health coverage for all. In this Perspective article, we discuss a range of science-based strategies, policies, and structural reforms to design an entire new disease prevention-centered science, educational, and healthcare system that maximizes both human and environmental health.
Author Correction: An inflammatory aging clock (iAge) based on deep learning tracks multimorbidity, immunosenescence, frailty and cardiovascular aging
Authors: Nazish Sayed, Yingxiang Huang, Khiem Nguyen, Zuzana Krejciova-Rajaniemi, Anissa P. Grawe, Tianxiang Gao, Robert Tibshirani, Trevor Hastie, Ayelet Alpert, Lu Cui, Tatiana Kuznetsova, Yael Rosenberg-Hasson, Rita Ostan, Daniela Monti, Benoit Lehallier, Shai S. Shen-Orr, Holden T. Maecker, Cornelia L. Dekker, Tony Wyss-Coray, Claudio Franceschi, Vladimir Jojic, François Haddad, José G. Montoya, Joseph C. Wu, Mark M. Davis, David Furman
Journal: Nature Aging (2021)
Trends in Liver Transplantation for Acute Alcohol-Associated Hepatitis During the COVID-19 Pandemic in the US
Authors: Therese Bittermann, Nadim Mahmud, Peter Abt
Journal: JAMA Network Open (2021)

This cohort study examines rates of adding patients with acute alcohol-associated hepatitis to the liver transplant waiting list and receipt of transplants by these patients in the US during the COVID-19 pandemic compared with before the pandemic.
PS3-5 Phase III study of palonosetron for preventing chemotherapy-induced nausea and vomiting in pediatric patients
Authors: Yuhki Koga, Yoshiyuki Kosaka, Katsuyoshi Koh, Kimikazu Matsumoto, Tadashi Kumamoto, Hiroyuki Fujisaki, Yuji Ishida, Ryoko Suzuki, Shinji Mochizuki, Hiroaki Goto, Yuki Yuza, Junichi Hara
Journal: Annals of Oncology (2021)
Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment
Authors: Xiaoyu Xu, Chang Liu, Yonghui Wang, Oliver Koivisto, Junnian Zhou, Yilai Shu, Hongbo Zhang
Journal: Advanced Drug Delivery Reviews (2021)

CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats-associated protein 9) is a potent technology for gene-editing. Owing to its high specificity and efficiency, CRISPR/Cas9 is extensity used for human diseases treatment, especially for cancer, which involves multiple genetic alterations. Different concepts of cancer treatment by CRISPR/Cas9 are established. However, significant challenges remain for its clinical applications. The greatest challenge for CRISPR/Cas9 therapy is how to safely and efficiently deliver it to target sites in vivo. Nanotechnology has greatly contributed to cancer drug delivery. Here, we present the action mechanisms of CRISPR/Cas9, its application in cancer therapy and especially focus on the nanotechnology-based delivery of CRISPR/Cas9 for cancer gene editing and immunotherapy to pave the way for its clinical translation. We detail the difficult barriers for CRISIR/Cas9 delivery in vivo and discuss the relative solutions for encapsulation, target delivery, controlled release, cellular internalization, and endosomal escape.
Changes in Attributable Fractions and Causal Inference for Schizophrenia and Other Psychiatric Outcomes
Authors: Tyler J. VanderWeele
Journal: JAMA Psychiatry (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Abstract 14242: Hospital Treatment Practices and Long-Term Outcomes of Patients with Acute Heart Failure with Preserved and Reduced Ejection Fraction
Authors: Aniruddha Singh, Theo E Meyer, Darleen Lessard, Robert J Goldberg
Journal: Circulation (2011)

Introduction: Few studies have examined the hospital treatment practices and long-term survival of patients with heart failure with preserved ejection fraction (HFPEF) and for those with reduced ej...
RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer
Authors: Kazuhiko Nakagawa, Ernest Nadal, Edward B. Garon, Makoto Nishio, Takashi Seto, Nobuyuki Yamamoto, Keunchil Park, Jin-Yuan Shih, Luis Paz-Ares, Bente Frimodt-Moller, Annamaria H. Zimmermann, Sameera Wijayawardana, Carla Visseren-Grul, Martin Reck
Journal: Clinical Cancer Research (2021)

Abstract Purpose: In EGFR-mutated metastatic non–small cell lung cancer (NSCLC), outcomes from EGFR tyrosine kinase inhibitors have differed historically by mutation type present, with lower benefit reported in patients with ex21L858R versus ex19del mutations. We investigated if EGFR-activating mutation subtypes impact treatment outcomes in the phase III RELAY study. Associations between EGFR mutation type and preexisting co-occurring and treatment-emergent genetic alterations were also explored. Patients and Methods: Patients with metastatic NSCLC, an EGFR ex19del or ex21L858R mutation, and no central nervous system metastases were randomized (1:1) to erlotinib (150 mg/day) with either ramucirumab (10 mg/kg; RAM+ERL) or placebo (PBO+ERL), every 2 weeks, until RECIST v1.1–defined progression or unacceptable toxicity. The primary endpoint was progression-free survival (PFS). Secondary and exploratory endpoints included overall response rate (ORR), duration of response (DOR), PFS2, time-to-chemotherapy (TTCT), safety, and next-generation sequencing analyses. Results: Patients with ex19del and ex21L858R mutations had similar clinical characteristics and comutational profiles. One-year PFS rates for ex19del patients were 74% for RAM+ERL versus 54% for PBO+ERL; for ex21L858R rates were 70% (RAM+ERL) versus 47% (PBO+ERL). Similar treatment benefits (ORR, DOR, PFS2, and TTCT) were observed in RAM+ERL–treated patients with ex19del and ex21L858R. Baseline TP53 comutation was associated with superior outcomes for RAM+ERL in both ex19del and ex21L858R subgroups. EGFR T790M mutation rate at progression was similar between treatment arms and by mutation type. Conclusions: RAM+ERL provided significant clinical benefit for both EGFR ex19del and ex21L858R NSCLC, supporting this regimen as suitable for patients with either of these EGFR mutation types.
Super-sensitive bifunctional nanoprobe: Self-assembly of peptide-driven nanoparticles demonstrating tumor fluorescence imaging and therapy
Authors: Han Xiao, Rui Zhang, Xiaobo Fan, Xinglu Jiang, Mingyuan Zou, Xuejiao Yan, Haiping Hao, Guoqiu Wu
Journal: Acta Pharmaceutica Sinica B (2021)

The development of nanomedicine has recently achieved several breakthroughs in the field of cancer treatment; however, biocompatibility and targeted penetration of these nanomaterials remain as limitations, which lead to serious side effects and significantly narrow the scope of their application. The self-assembly of intermediate filaments with arginine-glycine-aspartate (RGD) peptide (RGD-IFP) was triggered by the hydrophobic cationic molecule 7-amino actinomycin D (7-AAD) to synthesize a bifunctional nanoparticle that could serve as a fluorescent imaging probe to visualize tumor treatment. The designed RGD-IFP peptide possessed the ability to encapsulate 7-AAD molecules through the formation of hydrogen bonds and hydrophobic interactions by a one-step method. This fluorescent nanoprobe with RGD peptide could be targeted for delivery into tumor cells and released in acidic environments such as endosomes/lysosomes, ultimately inducing cytotoxicity by arresting tumor cell cycling with inserted DNA. It is noteworthy that the RGD-IFP/7-AAD nanoprobe tail-vein injection approach demonstrated not only high tumor-targeted imaging potential, but also potent antitumor therapeutic effects in vivo. The proposed strategy may be used in peptide-driven bifunctional nanoparticles for precise imaging and cancer therapy.
Abstract 16522: Immunosenescence-Associated MicroRNAs in Age and Heart Failure
Authors: Timon Seeger, Fatima Haffez, Ariane Fischer, Ulrike Köhl, Florian Seeger, Andreas M Zeiher, Dimmeler Stefanie
Journal: Circulation (2011)

Increasing age is a major risk factor for cardiovascular diseases and is associated with a decline of organ repair capacity. Aging of the immune system, immunosenescence, is characterized by an imp...
Aggregation‐Induced Emission (AIE) Nanoparticles‐Assisted NIR‐II Fluorescence Imaging‐Guided Diagnosis and Surgery for Inflammatory Bowel Disease (IBD)
Authors: Xiaoxiao Fan, Qiming Xia, Yiyin Zhang, Yirun Li, Zhe Feng, Jing Zhou, Ji Qi, Ben Zhong Tang, Jun Qian, Hui Lin
Journal: Advanced Healthcare Materials (2021)

Abstract The incidence of inflammatory bowel diseases (IBD), including Crohn's diseases and ulcerative colitis, is increasing by time and showing a trend of younger age. Precise diagnosis and effective treatments for IBD have attracted growing attention in recent years. However, diagnosing and locating inflammatory lesions remain a great challenge for IBD. In this study, assisted by a kind of aggregation‐induced emission (AIE) nanoprobes (BPN‐BBTD nanoparticles [NPs]), the second near‐infrared (NIR‐II) fluorescence imaging is first utilized to accurately trace inflammatory lesions, monitor inflammation severity and detect the response to the drug intervention in IBD mouse models. Through the advantages of high signal‐to‐background ratio (SBR) and sharp spatial resolution of bio‐imaging in NIR‐II region, the NIR‐II fluorescence imaging‐guided surgery can help to achieve a complete resection of severe inflammatory bowls and a secure surgical anastomosis. In addition, with the help of NIR‐II fluorescence wide‐field microscopy, the distribution of BPN‐BBTD NPs can be directly detected in tissue level and found to be mainly accumulated in mucosa and submucosa layers. This study highlights that AIE NPs‐assisted NIR‐II fluorescence imaging hold a great potential value for future diagnosis and imaging‐guided surgery in IBD.
P-14 The predictive value of alkaline phosphatase and lactate dehydrogenase for overall survival in patients with pancreatic cancer
Authors: A. Bengueddach, A. Tidjane, H. Kehili, N. Boudjenan Serradj, M. Kaid, B. Tabeti, F. Bereksi Reguig
Journal: Annals of Oncology (2021)
Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies
Authors: Shohei Koyama, Hiroyoshi Nishikawa
Journal: Journal for ImmunoTherapy of Cancer (2021)

With the broad application of cancer immunotherapies such as immune checkpoint inhibitors in multiple cancer types, the immunological landscape in the tumor microenvironment (TME) has become enormously important for determining the optimal cancer treatment. Tumors can be immunologically divided into two categories: inflamed and non-inflamed based on the extent of immune cell infiltration and their activation status. In general, immunotherapies are preferable for the inflamed tumors than for non-inflamed tumors. Regulatory T cells (Tregs), an immunosuppressive subset of CD4 + T cells, play an essential role in maintaining self-tolerance and immunological homeostasis. In tumor immunity, Tregs compromise immune surveillance against cancer in healthy individuals and impair the antitumor immune response in tumor-bearing hosts. Tregs, therefore, accelerate immune evasion by tumor cells, leading to tumor development and progression in various types of cancer. Therefore, Tregs are considered to be a crucial therapeutic target for cancer immunotherapy. Abundant Tregs are observed in the TME in many types of cancer, both in inflamed and non-inflamed tumors. Diverse mechanisms of Treg accumulation, activation, and survival in the TME have been uncovered for different tumor types, indicating the importance of understanding the mechanism of Treg infiltration in each patient when selecting the optimal Treg-targeted therapy. Here, we review recent advances in the understanding of mechanisms leading to Treg abundance in the TME to optimize Treg-targeted therapy. Furthermore, in addition to the conventional strategies targeting cell surface molecules predominantly expressed by Tregs, reagents targeting molecules and signaling pathways specifically employed by Tregs for infiltration, activation, and survival in each tumor type are illustrated as novel Treg-targeted therapies. The effectiveness of immune precision therapy depends on conditions in the TME of each cancer patient.
SIMPLE Is an Endosomal Regulator That Protects Against NAFLD by Targeting the Lysosomal Degradation of EGFR
Authors: Jingjing Song, Yupeng Liu, Juan Wan, Guang‐Nian Zhao, Jian‐Cheng Wang, Zhifei Dai, Sha Hu, Ling Yang, Zhen Liu, Yi Fu, Erdan Dong, Yi‐Da Tang
Journal: Hepatology (2021)

Background and Aims NAFLD has become a tremendous burden for public health; however, there is no drug for NAFLD therapy at present. Impaired endo-lysosome-mediated protein degradation is observed in a variety of metabolic disorders, such as atherosclerosis, type 2 diabetes mellitus, and NAFLD. Small integral membrane protein of lysosome/late endosome (SIMPLE) is a regulator of endosome-to-lysosome trafficking and cell signaling, but the role that SIMPLE plays in NAFLD progression remains unknown. Here we investigated SIMPLE function in NAFLD development and sophisticated mechanism therein. Approach and Results This study found that in vitro knockdown of SIMPLE significantly aggravated lipid accumulation and inflammation in hepatocytes treated with metabolic stimulation. Consistently, in vivo experiments showed that liver-specific Simple-knockout (Simple-HKO) mice exhibited more severe high-fat diet (HFD)–induced, high-fat-high-cholesterol diet (HFHC)–induced, and methionine-choline-deficient diet (MCD)–induced steatosis, glucose intolerance, inflammation, and fibrosis than those fed with normal chow (NC) diet. Meanwhile, RNA-sequencing demonstrated the up-regulated signaling pathways and signature genes involved in lipid metabolism, inflammation, and fibrosis in Simple-HKO mice compared with control mice under metabolic stress. Mechanically, we found SIMPLE directly interact with epidermal growth factor receptor (EGFR). SIMPLE deficiency results in dysregulated degradation of EGFR, subsequently hyperactivated EGFR phosphorylation, thus exaggerating NAFLD development. Moreover, we demonstrated that using EGFR inhibitor or silencing EGFR expression could ameliorate lipid accumulation induced by the knockdown of SIMPLE. Conclusions SIMPLE ameliorated NASH by prompting EGFR degradation and can be a potential therapeutic candidate for NASH.
Differentiation of exhausted CD8+ T cells after termination of chronic antigen stimulation stops short of achieving functional T cell memory
Authors: Pierre Tonnerre, David Wolski, Sonu Subudhi, Jihad Aljabban, Ruben C. Hoogeveen, Marcos Damasio, Hannah K. Drescher, Lea M. Bartsch, Damien C. Tully, Debattama R. Sen, David J. Bean, Joelle Brown, Almudena Torres-Cornejo, Maxwell Robidoux, Daniel Kvistad, Nadia Alatrakchi, Ang Cui, David Lieb, James A. Cheney, Jenna Gustafson, Lia L. Lewis-Ximenez, Lucile Massenet-Regad, Thomas Eisenhaure, Jasneet Aneja, W. Nicholas Haining, Raymond T. Chung, Nir Hacohen, Todd M. Allen, Arthur Y. Kim, Georg M. Lauer
Journal: Nature Immunology (2021)
Genetic errors of immunity distinguish pediatric nonmalignant lymphoproliferative disorders
Authors: Lisa R. Forbes, Olive S. Eckstein, Nitya Gulati, Erin C. Peckham-Gregory, Nmazuo W. Ozuah, Joseph Lubega, Nader K. El-Mallawany, Jennifer E. Agrusa, M. Cecilia Poli, Tiphanie P. Vogel, Natalia S. Chaimowitz, Nicholas L. Rider, Emily M. Mace, Jordan S. Orange, Jason W. Caldwell, Juan C. Aldave-Becerra, Stephen Jolles, Francesco Saettini, Hey J. Chong, Asbjorg Stray-Pedersen, Helen E. Heslop, Kala Y. Kamdar, R. Helen Rouce, Donna M. Muzny, Shalini N. Jhangiani, Richard A. Gibbs, Zeynep H. Coban-Akdemir, James R. Lupski, Kenneth L. McClain, Carl E. Allen, Ivan K. Chinn
Journal: Journal of Allergy and Clinical Immunology (2021)
Ajit Kumar Shah
Authors: Sofia Zarate Escudero, Shrenik Savla-Shah
Journal: BMJ (2021)

Ajit Kumar Shah was born in Eldoret, Kenya, and came to the UK as a teenager. He undertook medical training at Liverpool University. At the end of his psychiatry training in 1992, he went to work in Australia as consultant old age psychiatrist and academic associate at the University of Melbourne.

He returned to the UK in 1994 and worked as a consultant psychiatrist at West London Mental Health Trust until his retirement in 2010, as well as a senior lecturer at Imperial College until his appointment as professor of ageing, ethnicity, and mental health at the University of Central Lancashire in 2007. He was additional professor of psychiatry at Hallym University Medical School, Seoul, South Korea, from 2009-14. …
Uncertainty in Medicine
Authors: Alexander Chaitoff
Journal: JAMA Internal Medicine (2021)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Association of the dysfunctional placentation endotype of prematurity with bronchopulmonary dysplasia: a systematic review, meta-analysis and meta-regression
Authors: Maria Pierro, Eduardo Villamor-Martinez, Elke van Westering-Kroon, Maria Alvarez-Fuente, Steven H Abman, Eduardo Villamor
Journal: Thorax (2021)

Background Antenatal pathological conditions are key in the pathogenesis of bronchopulmonary dysplasia (BPD). Pathophysiological pathways or endotypes leading to prematurity and perinatal lung injury can be clustered into two groups: infection and dysfunctional placentation, which include hypertensive disorders of pregnancy (HDP) and intrauterine growth restriction (IUGR). We conducted a systematic review of observational studies exploring the association between the dysfunctional placentation endotype and BPD. Methods MEDLINE, Embase and Web of Science databases were searched up to February 2020 for studies reporting data on the diagnosis of HDP, IUGR or small for gestational age (SGA) and BPD risk. BPD was classified as BPD28 (supplemental oxygen on day 28), BPD36 (oxygen at 36 weeks postmenstrual age), severe BPD (≥ 30% oxygen or mechanical ventilation), BPD36/death and BPD-associated pulmonary hypertension. Results Of 6319 studies screened, 211 (347 963 infants) were included. Meta-analysis showed an association between SGA/IUGR and BPD36 (OR 1.56, 95% CI 1.37 to 1.79), severe BPD (OR 1.82, 95% CI 1.36 to 2.29) and BPD/death (OR 1.91, 95% CI 1.55 to 2.37). Exposure to HDP was not associated with BPD but was associated with decreased odds of BPD/death (OR 0.77, 95% CI 0.64 to 0.94). Both HDP (OR 1.41, 95% CI 1.10 to 1.80) and SGA/IUGR (OR 2.37, 95% CI 1.86 to 3.02) were associated with BPD-associated pulmonary hypertension. Conclusion When placental vascular dysfunction is accompanied by fetal growth restriction or being born SGA, it is associated with an increased risk of developing BPD and pulmonary hypertension. The placental dysfunction endotype of prematurity is strongly associated with the vascular phenotype of BPD. Prospero registration number Review protocol was registered in PROSPERO database (ID=CRD42018086877).